Rynki
Co znajdą Państwo na tej stronie
Każdy rynek ma osobną podstronę z nazwą regulatora, opublikowanym stanowiskiem i każdym źródłem, opatrzonym datą i linkiem do instytucji, która je wydała. Dzięki temu każde stwierdzenie można sprawdzić u źródła.
Strona obejmuje 35 rynków i 141 źródeł z datą. Ostatni przegląd: 2026-08-20.
Podstrony poszczególnych rynków są na razie opublikowane w języku angielskim.
Tabela pozycji regulacyjnych
Poniżej znajduje się tabela pozycji regulacyjnych według związku i rynku. Pokazuje, co dany regulator opublikował na temat danego związku, ze źródłem przy każdej komórce.
Jak korzystamy z tych danych
To jest ten sam materiał, z którego korzystamy sami, gdy nabywca pyta, czy dany związek może zostać dostarczony na jego rynek. Publikujemy go, aby odpowiedź była dostępna, zanim Państwo o nią zapytają.
Informacje na tej stronie nie stanowią porady prawnej. Pełne warunki dostawy są określone w naszych warunkach handlowych.
Enquiry
| Market | Code | Sources | Summary |
|---|---|---|---|
| Britain and Ireland2 | |||
| Ireland (EN) | IE | 2 sources | The HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is Englis... |
| United Kingdom (EN) | GB | 7 sources | The United Kingdom prohibits the sale or supply of any unauthorised medicinal product outright under the... |
| German-speaking markets3 | |||
| Austria (EN) | AT | 3 sources | BASG has published a dedicated position holding that a research-use label does not change a peptide's cl... |
| Germany (EN) | DE | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and sets criminal thresholds f... |
| Switzerland (EN) | CH | 5 sources | Swissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agen... |
| Benelux2 | |||
| Belgium (EN) | BE | 3 sources | Belgium applies EU medicines law through the FAGG, which has published a GLP-1 warning. No dedicated pos... |
| Netherlands (EN) | NL | 3 sources | The IGJ and the NVWA assess offerings jointly and have stated their position on research-use framing dir... |
| Nordics5 | |||
| Denmark (EN) | DK | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Research-chemical framing is a... |
| Finland (EN) | FI | 2 sources | Fimea has warned against injectable peptides sold through social media. Semaglutide is a prescription me... |
| Iceland (EN) | IS | 6 sources | Iceland applies the Medicinal Products Act No. 100/2020, administered by the Icelandic Medicines Agency.... |
| Norway (EN) | NO | 8 sources | Norway applies the legemiddelloven and criminalises trade in listed doping substances under the general ... |
| Sweden (EN) | SE | 5 sources | Lakemedelsverket has a published position on Melanotan II, and a government-commissioned report quantifi... |
| Baltics3 | |||
| Estonia (EN) | EE | 2 sources | Ravimiamet published a dated statement in June 2026 addressing internet-sold peptides marketed for resea... |
| Latvia (EN) | LV | 4 sources | The ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No pe... |
| Lithuania (EN) | LT | 4 sources | The VVKT regulates under the Farmacijos istatymas and requires a wholesale distribution licence. No posi... |
| Central and Eastern Europe6 | |||
| Croatia (EN) | HR | 1 sources | HALMED has published a general rule on online medicine sales. No notice naming research-labelled peptide... |
| Czechia (EN) | CZ | 2 sources | SUKL holds that most synthetic peptides meet the functional definition of a medicinal product, so classi... |
| Hungary (EN) | HU | 5 sources | OGYEI regulates medicines under Act XCV of 2005. A case-by-case research permit exists for controlled su... |
| Poland (EN) | PL | 2 sources | GIF and GIS have issued a joint public warning on synthetic peptides offered as chemical reagents. The P... |
| Slovakia (EN) | SK | 3 sources | SUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press release tied to an INTERPOL o... |
| Slovenia (EN) | SI | 2 sources | JAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropi... |
| Southern Europe4 | |||
| France (EN) | FR | 3 sources | ANSM names compounds individually in its public alerts and has issued sanitary-police decisions against ... |
| Italy (EN) | IT | 1 sources | AIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised ... |
| Portugal (EN) | PT | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a rise in illegal online su... |
| Spain (EN) | ES | 2 sources | AEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to verify pharmacies through... |
| Eastern Mediterranean2 | |||
| Greece (EN) | GR | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific compounds. Regulatory att... |
| Turkey (EN) | TR | 6 sources | Turkey applies Law No. 1262 on Pharmaceutical and Medicinal Preparations of 1928 together with the regul... |
| Western Balkans4 | |||
| Albania (EN) | AL | 7 sources | Albania applies Law no. 105/2014 on medicinal products and the pharmaceutical service, as amended, admin... |
| Bosnia and Herzegovina (EN) | BA | 5 sources | Bosnia and Herzegovina applies a single state-level act, the Law on Medicinal Products and Medical Devic... |
| North Macedonia (EN) | MK | 7 sources | North Macedonia applies the Law on Medicines and Medical Devices, published in the official gazette in 2... |
| Serbia (EN) | RS | 5 sources | Serbia applies the Law on Medicines and Medical Devices, published in the official gazette in 2010 and a... |
| Eastern Europe2 | |||
| Moldova (EN) | MD | 6 sources | Moldova replaced its medicines statute in 2025: Law No. 153 of 19 June 2025 was published in the officia... |
| Ukraine (EN) | UA | 6 sources | Ukraine regulates medicines under the Law on Medicinal Products of 4 April 1996, enforced by the State S... |
| South-eastern EU2 | |||
| Bulgaria (EN) | BG | 5 sources | The BDA regulates under the national medicines law and participates in the EU counterfeit-GLP-1 warning ... |
| Romania (EN) | RO | 3 sources | ANMDMR operates under the EU medicines framework and has publicly identified a fraudulent tirzepatide pr... |